Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Read on today for some exclusive hiring news and a retraction of a high-profile paper on cancer detection.

advertisement

The need-to-know this morning

  • The FDA rejected a HER3 antibody drug conjugate from Daiichi Sankyo and Merck. The two companies, which signed a multibillion-dollar partnership last year, blamed the rejection on manufacturing issues.
  • AbbVie and Genmab won accelerated approval for Epkinly, a bispecific antibody; it will compete with CAR-T therapy and a Roche bispecific.
  • Verona Pharma won approval for an inhalable COPD drug, now marketed as Ohtuvayre.

CDC advisers opt for go-slow approach with RSV vaccine recommendation

Though the current RSV vaccines on the market (from GSK, Pfizer, and Moderna) are approved for adults 60 and older, a CDC advisory panel yesterday recommended the vaccines for a just a subgroup of that population — people 75 and older and people 60 to 74 years old with a high-risk condition. Those aged 60 to 74 who aren’t at high risk may still get a vaccine if they want to, but insurers are unlikely to cover it for them without the  recommendation of the CDC and its advisory panel, the Advisory Committee on Immunization Practices.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.